205P Modelling of NSCLC aPD1 responses in bronchoscopc biopsies on chip (bronchoBOCs)

Eligibility for aPD1 therapy is based on PD-L1 expression, but few patients experience durable responses. Tumours cultured in microfluidic devices (tumour-on-chip) recapitulate the vivo microenvironment and are being developed as drug screening platforms. Their application to advanced NSCLC hampered by unavailability of surgical tumour resection specimens these patients. To overcome this, we aimed develop a methodological approach that will allow culture bronchoscopic biopsies chips model Bronchoscopic from 25 were dissected filtered obtain spheroids 40–100 µm size (3 × 105 spheroids/biopsy). AIM biotech consisting central channel 2 lateral channels used. Tumour dispersed matrigel split chips. Endothelial cells at mimic vasculature. Pembrolizumab (aPD1) vs isotype control was administered (10 µg/mL). After 48 h effluents analysed cytometric bead array (CBA) cytokines cytotoxic molecules. Spheroids, along with effluents, mass spectrometry (LC MS/MS). CBA analysis showed robust increase release granzyme B granulysin, used T kill cancer cells, pembrolizumab-exposed effluents. LC MS/MS identified 122 differentially abundant proteins pembrolizumab-treated 71 Pathway enrichment suggested pembrolizumab activated innate adaptive immune responses signal transduction pathways bronchoBOCs. We first bronchoBOCs physiologically-relevant aPD1. envisage use biomarker identification, platform our mechanistic understanding human immunity.